We saw a strong performance by major biotech players, but a challenging environment for the rest of the industry. Read more in our 2013 industry report
Beyond Borders: global biotech report 2013
Life Sciences deal sentiment scorecard
mHealth: Mobile tech poised to enable new era in health care
Pharma's $100 billion growth gap
Cash on the prescription 2012
Beyond borders: global biotech report 2012
Progressions 2012: health care everywhere
What Europe has to offer biotechnology companies
Medical technology report 2011
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
1-2 November 2012
Philadelphia, Pennsylvania (US)
Presented by Ernst & Young and Real Endpoints
Join us at this premier event which brings together senior executives from leading product (pharma, medtech, biotech) companies along with payers, providers and policymakers to discuss the key issues that will set the product reimbursement agenda over the next few years.